299 related articles for article (PubMed ID: 22249590)
21. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
[TBL] [Abstract][Full Text] [Related]
22. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
23. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas.
Khalid-de Bakker CA; Jonkers DM; Sanduleanu S; de Bruïne AP; Meijer GA; Janssen JB; van Engeland M; Stockbrügger RW; Masclee AA
Cancer Prev Res (Phila); 2011 Oct; 4(10):1563-71. PubMed ID: 21750209
[TBL] [Abstract][Full Text] [Related]
24. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
25. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
Park DI; Ryu S; Kim YH; Lee SH; Lee CK; Eun CS; Han DS
Am J Gastroenterol; 2010 Sep; 105(9):2017-25. PubMed ID: 20502450
[TBL] [Abstract][Full Text] [Related]
26. [Lesions Detected in Six Spanish Colorectal Cancer Screening Population Based Programmes. CRIBEA Project. Spain].
Portillo Villares I; Arana-Arri E; Idigoras Rubio I; Espinás Piñol JA; Pérez Riquelme F; de la Vega Prieto M; González Aledo A; Oceja Setien E; Vanaclocha Espi M; Ibáñez Cabanell J; Salas Trejo D;
Rev Esp Salud Publica; 2017 Feb; 91():. PubMed ID: 28218734
[TBL] [Abstract][Full Text] [Related]
27. Comparative evaluation of two colorectal cancer screening campaigns using different faecal occult blood tests in a French area.
Cariou M; El Fettouhi A; Kermarrec T; Bommelaere F; Foll Y; Nousbaum JB; Robaszkiewicz M; Quénéhervé L
Cancer Epidemiol; 2020 Dec; 69():101839. PubMed ID: 33096500
[TBL] [Abstract][Full Text] [Related]
28. The mean number of adenomas per procedure should become the gold standard to measure the neoplasia yield of colonoscopy: a population-based cohort study.
Denis B; Sauleau EA; Gendre I; Exbrayat C; Piette C; Dancourt V; Foll Y; Ait Hadad H; Bailly L; Perrin P
Dig Liver Dis; 2014 Feb; 46(2):176-81. PubMed ID: 24054769
[TBL] [Abstract][Full Text] [Related]
29. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
[TBL] [Abstract][Full Text] [Related]
30. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
31. Potential for prevention: a cohort study of colonoscopies and removal of adenomas in a FIT-based colorectal cancer screening programme.
Larsen MB; Njor SH; Jensen TM; Ingeholm P; Andersen B
Scand J Gastroenterol; 2019 Aug; 54(8):1008-1014. PubMed ID: 31397598
[No Abstract] [Full Text] [Related]
32. Clinical outcomes from the CDC's Colorectal Cancer Screening Demonstration Program.
Seeff LC; Royalty J; Helsel WE; Kammerer WG; Boehm JE; Dwyer DM; Howe WR; Joseph D; Lane DS; Laughlin M; Leypoldt M; Marroulis SC; Mattingly CA; Nadel MR; Phillips-Angeles E; Rockwell TJ; Ryerson AB; Tangka FK
Cancer; 2013 Aug; 119 Suppl 15():2820-33. PubMed ID: 23868476
[TBL] [Abstract][Full Text] [Related]
33. Immunological fecal occult blood test vs. serum ferritin for detection of colorectal neoplasia in high risk asymptomatic population.
Sobrino-Cossío S; Fenocchi E; Hernández-Guerrero A; Alonso-Lárraga JO; De la Mora-Levy JG; Larracilla-Salazar I
Rev Gastroenterol Mex; 2011; 76(3):191-8. PubMed ID: 22041307
[TBL] [Abstract][Full Text] [Related]
34. Colon capsule endoscopy as possible filter test for colonoscopy selection in a screening population with positive fecal immunology.
Holleran G; Leen R; O'Morain C; McNamara D
Endoscopy; 2014 Jun; 46(6):473-8. PubMed ID: 24824091
[TBL] [Abstract][Full Text] [Related]
35. Risk stratification and detection of new colorectal neoplasms after colorectal cancer screening with faecal occult blood test: experiences from a Danish screening cohort.
Bjerrum A; Milter MC; Andersen O; Fischer A; Lynge E
Eur J Gastroenterol Hepatol; 2015 Dec; 27(12):1433-7. PubMed ID: 26352132
[TBL] [Abstract][Full Text] [Related]
36. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.
Rozen P; Comaneshter D; Levi Z; Hazazi R; Vilkin A; Maoz E; Birkenfeld S; Niv Y
Cancer; 2010 May; 116(9):2115-25. PubMed ID: 20186820
[TBL] [Abstract][Full Text] [Related]
37. [Screening for colorectal cancer in Italy, 2010 survey].
Zorzi M; Fedato C; Grazzini G; Sassoli de' Bianchi P; Naldoni C; Pendenza M; Sassatelli R; Senore C; Visioli CB; Zappa M
Epidemiol Prev; 2012; 36(6 Suppl 1):55-77. PubMed ID: 23293271
[TBL] [Abstract][Full Text] [Related]
38. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program.
Chiang TH; Chuang SL; Chen SL; Chiu HM; Yen AM; Chiu SY; Fann JC; Chou CK; Lee YC; Wu MS; Chen HH
Gastroenterology; 2014 Dec; 147(6):1317-26. PubMed ID: 25200099
[TBL] [Abstract][Full Text] [Related]
39. Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels.
Toes-Zoutendijk E; van Leerdam ME; Dekker E; van Hees F; Penning C; Nagtegaal I; van der Meulen MP; van Vuuren AJ; Kuipers EJ; Bonfrer JMG; Biermann K; Thomeer MGJ; van Veldhuizen H; Kroep S; van Ballegooijen M; Meijer GA; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I;
Gastroenterology; 2017 Mar; 152(4):767-775.e2. PubMed ID: 27890769
[TBL] [Abstract][Full Text] [Related]
40. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
